- RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
This study looks for new ways to treat advanced oesophageal cancer that has spread or can't be removed by surgery. It combines existing immunotherapy (pembrolizumab) with new experimental drugs, sometimes with chemotherapy. The main goal is to check safety and how well these treatments work.
For: Esophageal Squamous Cell CarcinomaUnited States · Brazil · Chile - RecruitingPHASE1, PHASE2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This study looks at new drug combinations with a medicine called pembrolizumab and chemotherapy for advanced stomach or oesophageal cancer that can't be removed by surgery. It's in early stages (Phase 1/2) and aims to find safe doses and see how well the treatments work.
For: Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal NeoplasmsUnited States · Brazil · Chile - Active not recruitingPHASE2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This study is testing a new drug, futibatinib, alongside standard cancer treatments for people with advanced oesophageal or pancreatic cancer. We want to see if this new combination helps fight the cancer and how safe it is.
For: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer · Esophageal Adenocarcinoma · Esophageal Squamous Cell CancerUnited States · France · Germany - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
For: Metastatic Esophageal Squamous Cell CarcinomaUnited States · Argentina · Canada - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
This study looks at a new drug, pembrolizumab, for certain types of oesophageal cancer. It compares giving pembrolizumab alongside standard chemotherapy and radiotherapy with giving a dummy drug (placebo) with the same standard treatment. We want to see if the new drug can help people live longer or prevent the cancer from coming back.
For: Esophageal Squamous Cell Carcinoma (ESCC) · Gastroesophageal Junction Carcinoma (GEJC) · Esophageal Adenocarcinoma (EAC)United States · Argentina · Belgium